Xiao‐Feng Le

1.2k total citations
29 papers, 891 citations indexed

About

Xiao‐Feng Le is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Xiao‐Feng Le has authored 29 papers receiving a total of 891 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Molecular Biology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Xiao‐Feng Le's work include Spine and Intervertebral Disc Pathology (8 papers), Spinal Fractures and Fixation Techniques (8 papers) and HER2/EGFR in Cancer Research (5 papers). Xiao‐Feng Le is often cited by papers focused on Spine and Intervertebral Disc Pathology (8 papers), Spinal Fractures and Fixation Techniques (8 papers) and HER2/EGFR in Cancer Research (5 papers). Xiao‐Feng Le collaborates with scholars based in United States, China and South Korea. Xiao‐Feng Le's co-authors include Robert C. Bast, Weiqun Mao, George A. Călin, Wei Tian, Erica Moretti, Francisco J. Esteva, Angelo Di Leo, Aman U. Buzdar, Libero Santarpia and Ju‐Yeon Kim and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Cancer.

In The Last Decade

Xiao‐Feng Le

29 papers receiving 887 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiao‐Feng Le United States 15 475 303 214 202 185 29 891
Martin Werner Germany 12 319 0.7× 192 0.6× 226 1.1× 119 0.6× 252 1.4× 21 837
Wen‐Ling Kuo Taiwan 15 266 0.6× 196 0.6× 193 0.9× 75 0.4× 192 1.0× 60 805
Yiyan Lei China 20 434 0.9× 244 0.8× 173 0.8× 102 0.5× 318 1.7× 70 1.0k
Arihiro Aihara Japan 19 513 1.1× 327 1.1× 180 0.8× 71 0.4× 408 2.2× 45 999
Zengli Liu China 16 444 0.9× 253 0.8× 240 1.1× 59 0.3× 210 1.1× 48 739
Xiaolong Wu China 14 317 0.7× 231 0.8× 102 0.5× 127 0.6× 241 1.3× 70 723
Yangfan Lv China 16 583 1.2× 359 1.2× 87 0.4× 86 0.4× 205 1.1× 31 892
Hien Dang United States 15 479 1.0× 268 0.9× 107 0.5× 102 0.5× 376 2.0× 24 1.0k
Zhenggang Ren China 18 399 0.8× 288 1.0× 338 1.6× 102 0.5× 444 2.4× 40 1.1k
Klaas M. Govaert Netherlands 15 330 0.7× 191 0.6× 104 0.5× 63 0.3× 314 1.7× 23 690

Countries citing papers authored by Xiao‐Feng Le

Since Specialization
Citations

This map shows the geographic impact of Xiao‐Feng Le's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiao‐Feng Le with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiao‐Feng Le more than expected).

Fields of papers citing papers by Xiao‐Feng Le

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiao‐Feng Le. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiao‐Feng Le. The network helps show where Xiao‐Feng Le may publish in the future.

Co-authorship network of co-authors of Xiao‐Feng Le

This figure shows the co-authorship network connecting the top 25 collaborators of Xiao‐Feng Le. A scholar is included among the top collaborators of Xiao‐Feng Le based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiao‐Feng Le. Xiao‐Feng Le is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Piha‐Paul, Sarina A., Chieh Tseng, Hai T. Tran, et al.. (2025). Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations. ESMO Open. 10(2). 104136–104136. 2 indexed citations
2.
3.
Mazières, Julien, Marie Wislez, Christophe Dooms, et al.. (2022). LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study. Annals of Oncology. 33. S1419–S1420. 27 indexed citations
4.
Le, Xiao‐Feng, et al.. (2021). Psychometric Properties of the Chinese Version of the Sarcopenia and Quality of Life, a Quality of Life Questionnaire Specific for Sarcopenia. Calcified Tissue International. 109(4). 415–422. 15 indexed citations
5.
Xu, Yunfeng, Xiao‐Feng Le, Qi Zhang, et al.. (2020). Superior-segment Bilateral Facet Violation in Lumbar Transpedicular Fixation, Part I. Spine. 45(11). E624–E630. 4 indexed citations
6.
Hong, David S., Lyudmila Bazhenova, Byoung Chul Cho, et al.. (2020). First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET. European Journal of Cancer. 138. S1–S1. 6 indexed citations
7.
Xu, Yunfeng, Qi Zhang, Xiao‐Feng Le, et al.. (2019). Comparison of the One-Time Accuracy of Simulated Freehand and Navigation Simulated Pedicle Screw Insertion. World Neurosurgery. 128. e347–e354. 4 indexed citations
8.
9.
Le, Xiao‐Feng, et al.. (2019). Incidence and Risk Factors of Superior Facet Joint Violation in Percutaneous and Open Instrumentation Using Cortical Bone Trajectory Technique. Clinical Spine Surgery A Spine Publication. 33(3). E127–E134. 1 indexed citations
10.
Le, Xiao‐Feng, Wei Tian, Xiaoguang Han, et al.. (2018). Robot-Assisted Versus Fluoroscopy-Assisted Cortical Bone Trajectory Screw Instrumentation in Lumbar Spinal Surgery: A Matched-Cohort Comparison. World Neurosurgery. 120. e745–e751. 97 indexed citations
11.
Xu, Yunfeng, Xiao‐Feng Le, Bo Liu, et al.. (2018). Computer-assisted, minimally invasive transforaminal lumbar interbody fusion. Medicine. 97(27). e11423–e11423. 14 indexed citations
12.
Ji, Yuanyuan, Zhidong Wang, Zongfang Li, et al.. (2016). Angiotensin II Enhances Proliferation and Inflammation through AT1/PKC/NF-κB Signaling Pathway in Hepatocellular Carcinoma Cells. Cellular Physiology and Biochemistry. 39(1). 13–32. 35 indexed citations
13.
Ji, Yuanyuan, et al.. (2012). Angiotensin II Induces Angiogenic Factors Production Partly Via AT1/JAK2/STAT3/SOCS3 Signaling Pathway in MHCC97H Cells. Cellular Physiology and Biochemistry. 29(5-6). 863–874. 37 indexed citations
14.
Shackleford, Terry J., Qingxiu Zhang, Ling Tian, et al.. (2011). Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells. Breast Cancer Research. 13(3). R65–R65. 47 indexed citations
15.
Santarpia, Libero, Ju‐Yeon Kim, Francisco J. Esteva, et al.. (2011). Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 118(10). 2603–2614. 221 indexed citations
16.
Le, Xiao‐Feng, Weiqun Mao, Zhen Lü, Bing Z. Carter, & Robert C. Bast. (2010). Dasatinib induces autophagic cell death in human ovarian cancer. Cancer. 116(21). 4980–4990. 71 indexed citations
17.
Jiang, Lili, Michelle K.Y. Siu, Kar Fai Tam, et al.. (2010). Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers. Molecular Cancer. 9(1). 318–318. 41 indexed citations
18.
Samanta, Ajoy K., Helen J. Huang, Xiao‐Feng Le, et al.. (2009). MEKK3 expression correlates with nuclear factor κ B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer. 115(17). 3897–3908. 23 indexed citations
19.
Le, Xiao‐Feng, Weiqun Mao, Isabelle Bedrosian, et al.. (2005). Growth arrest induced by anti-HER2 antibody blocks breast cancer cells in the late G1 phase of the cell cycle. Cancer Research. 65. 533–533. 5 indexed citations
20.
Le, Xiao‐Feng, David Gold, Yiling Lu, et al.. (2004). Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling. Journal of Biological Chemistry. 280(3). 2092–2104. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Werner Breakdown of academic impact, for papers by Wen‐Ling Kuo Breakdown of academic impact, for papers by Yiyan Lei Breakdown of academic impact, for papers by Arihiro Aihara Breakdown of academic impact, for papers by Zengli Liu Breakdown of academic impact, for papers by Xiaolong Wu Breakdown of academic impact, for papers by Yangfan Lv Breakdown of academic impact, for papers by Hien Dang Breakdown of academic impact, for papers by Zhenggang Ren Breakdown of academic impact, for papers by Klaas M. Govaert
Rankless by CCL
2026